U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H20ClN3
Molecular Weight 289.803
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLOROPYRAMINE

SMILES

CN(C)CCN(CC1=CC=C(Cl)C=C1)C2=CC=CC=N2

InChI

InChIKey=ICKFFNBDFNZJSX-UHFFFAOYSA-N
InChI=1S/C16H20ClN3/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14/h3-10H,11-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C16H20ClN3
Molecular Weight 289.803
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Chloropyramine is an antagonist of H1 histamine receptors. It is indicated for the treatment of various forms of allergic reactions. Chloropyramine is a drug capable of (1) inhibiting the biochemical function of VEGFR-3 and FAK, (2) inhibiting proliferation of a diverse set of cancer cell types in vitro, and (3) reducing tumor growth in vivo.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
ALLERGOSAN

PubMed

Sample Use Guides

In Vivo Use Guide
Composition: One ampoule of 2 ml contains 20 mg chloropyramine hydrochloride (10 mg/ml). One coated tablet contains 25 mg chloropyramine hydrochloride. 1 g of ointment (1%) contains 10 mg chloropyramine hydrochloride. 1 g of cream (1%) contains 10 mg chloropyramine hydrochloride. Dosage and administration: Parenteral administration: in severe allergic reactions 1-2 ampoules intramuscularly or intravenously. Oral administration: adults - 25 mg (1 tabl.) 3-4 times daily (up to 150 mg, if necessary); children over 5 years: 1 tablet, 2-3 times daily. External application: affected area should be treated once or several times a day by applying a thin layer of ointment or cream.
Route of Administration: Other
In Vitro Use Guide
SKN-AS and SK-N-BE(2) neuroblastoma cells were treated with varying concentrations of chloropyramine hydrochloride (C4) for 24 h and cellular viability was measured. Both cell lines demonstrated a decrease in survival that was signifi-cant at 100 μM concentration. The calculated LC50 for C4 was similar in the two cell lines at 170 μM in the SK-N-AS cell line and 144 mM in the SK-N-BE(2) cell line.
Substance Class Chemical
Record UNII
2K3L8O9SOV
Record Status Validated (UNII)
Record Version